Evidence map›Paper›PMID 25598440›Full record

ArticleBritish journal of pharmacology2015

The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner.

T Joshi, M Johnson, R Newton, M A Giembycz

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  2. Review
  3. Review
  4. Activation of βArchives of pharmacal research · 2021
    Review
  5. Article
  6. Review
  7. Long-ActingMolecular pharmacology · 2018
    Article
  8. Article
  9. Long-acting βAmerican journal of physiology. Lung cellular and molecular physiology · 2017
    Article
  10. 15-Deoxy-Delta-12,14-Prostaglandin JFrontiers in immunology · 2017
    Article
  11. Understanding how long-acting βBritish journal of pharmacology · 2016
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

T JoshiDepartment of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
M Johnson
R Newton
M A Giembycz
University of Calgary · CAGlaxoSmithKline (United Kingdom) · GB

Funding

Canadian Institutes of Health Research MOP68828Canadian Institutes of Health Research MOP93742
6 · The paper itself

Abstract

background and purposeInhaled glucocorticoid (ICS)/long-acting β2 -adrenoceptor agonist (LABA) combination therapy is a recommended treatment option for patients with moderate/severe asthma in whom adequate control cannot be achieved by an ICS alone. Previously, we discovered that LABAs can augment dexamethasone-inducible gene expression and proposed that this effect may explain how these two drugs interact to deliver superior clinical benefit. Herein, we extended that observation by analysing, pharmacodynamically, the effect of the LABA, indacaterol, on glucocorticoid receptor (GR)-mediated gene transcription induced by seven ligands with intrinsic activity values that span the spectrum of full agonism to antagonism. EXPERIMENTAL APPROACH: BEAS-2B human airway epithelial cells stably transfected with a 2× glucocorticoid response element luciferase reporter were used to model gene transcription together with an analysis of several glucocorticoid-inducible genes. KEY

resultsIndacaterol augmented glucocorticoid-induced reporter activation in a manner that was positively related to the intrinsic activity of the GR agonist. This effect was demonstrated by an increase in response maxima without a change in GR agonist affinity or efficacy. Indacaterol also enhanced glucocorticoid-inducible gene expression. However, the magnitude of this effect was dependent on both the GR agonist and the gene of interest. CONCLUSIONS AND IMPLICATIONS: These data suggest that indacaterol activates a molecular rheostat, which increases the transcriptional competency of GR in an agonist- and gene-dependent manner without apparently changing the relationship between fractional GR occupancy and response. These findings provide a platform to rationally design ICS/LABA combination therapy that is based on the generation of agonist-dependent gene expression profiles in target and off-target tissues.

Indexed as

Adrenergic beta-2 Receptor AgonistsBenzodioxolesCells, CulturedColforsinDexamethasoneDrug InteractionsEpithelial CellsHumansIndansLigandsQuinolonesReceptors, GlucocorticoidRespiratory MucosaResponse ElementsSteroidsTranscriptional ActivationAdrenergic beta-2 Receptor AgonistsBenzodioxolesColforsinDexamethasonedexamethasone 21-methanesulfonateindacaterolIndansLigandsOrg 34517QuinolonesReceptors, GlucocorticoidSteroids

Identifiers

PMID25598440
PMCPMC4409912
OpenAlexW1538884896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.